A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01483690

Recruitment Status : Terminated (Toxicity)

First Posted : December 1, 2011

Last Update Posted : November 24, 2015

Sponsor:

Information provided by (Responsible Party):

Therapeutic Advances in Childhood Leukemia Consortium

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	June 2015
Study Completion Date :	No date given

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis ML, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Dubois SG, Pollard JA, Glade-Bender J, Cooper TM, Kaplan JA, Farooqi MS, Yoo B, Guest E, Wayne AS, Brown PA. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. Clin Cancer Res. 2020 Jan 22. pii: clincanres.1251.2019. doi: 10.1158/1078-0432.CCR-19-1251. [Epub ahead of print]

Raetz EA, Bhatla T. Where do we stand in the treatment of relapsed acute lymphoblastic leukemia? Hematology Am Soc Hematol Educ Program. 2012;2012:129-36. doi: 10.1182/asheducation-2012.1.129. Review.

To Top